References
- Glazener, CM, Evans, JH. Desmopressin for nocturnal enuresis. Cochrane Database Syst Rev. 2002; 3, CD002112.
- Glazener CM, Evans JH. Alarm interventions for nocturnal enuresis in children (Cochrane Review). The Cochrane Library. Update Software, Oxford 2007
- Nevéus T, Tullus K. Tolterodine and imipramine in refractory enuresis; a randomized, double-blind, placebo-controlled cross-over study. Pediatr Nephrol 2007; 23: 263–7
- Lovering JS, Tallett SE, McKendry BI. Oxybutynin efficacy in the treatment of primary enuresis. Pediatrics 1988; 82: 104–6
- Austin PF, Ferguson G, Yan Y, Campigotto MJ, Royer ME, Coplen DE. Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: randomized, double-blind, placebo-controlled trial. Pediatrics 2008; 122: 1027–32
- Gepertz S, Nevéus T. Imipramine for therapy resistant enuresis: a retrospective evaluation. J Urol 2004; 171: 2607–10
- Danysz W, Kostowski W, Hauptmann M. Evidence for the locus coeruleus involvement in desipramine action in animal models of depression. Pol J Pharmacol Pharm 1985; 37: 855–64
- Aston-Jones G, Rajkowski J, Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog Brain Res 2000; 126: 165–82
- Sasa M, Yoshimura N. Locus coeruleus noradrenergic neurons as a micturition center. Microsc Res Tech 1994; 29: 226–30
- Lightman SL, Todd K, Everitt BJ. Ascending noradrenergic projections from the brainstem: evidence for a major role in the regulation of blood pressure and vasopressin secretion. Exp Brain Res 1984; 55: 145–51
- Varley CK. Sudden death of a child treated with imipramine. Case study. J Child Adolesc Psychopharmachol 2000; 10: 321–5
- Kasper S, el Giamal N, Hilger E. Reboxetine : the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother 2000; 1: 771–82
- Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six -week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 428–33
- Toren P, Ratner S, Laor N, Lerer-Amisar D, Weizman A. A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series. Neuropsychobiology 2005; 51: 239–42
- Nevéus T. Reboxetine in therapy-resistant enuresis – results and pathogenetic implications. Scand J Urol Nephrol 2006; 40: 31–4
- Nevéus T, von Gontard A, Hoebeke P, Hjälmås K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the standardisation committee of the International Children's Continence Society (ICCS). J Urol 2006; 176: 314–24